<DOC>
	<DOCNO>NCT01610050</DOCNO>
	<brief_summary>This study evaluate safety tolerability determine MTD/RD .</brief_summary>
	<brief_title>A Phase I Study LFA102 Japanese Patients</brief_title>
	<detailed_description>This phase I open-label , multi-center , dose escalation study Japanese patient CRPC advance BC . LFA102 administer intravenously every 4 week study . All patient remain treatment meet criterion study discontinuation ( e.g . disease progression , unacceptable toxicity , patient withdrawal ) study closure . This study evaluate safety , pharmacokinetics , pharmacodynamics , preliminary anti-tumor activity LFA102 . Each cohort enroll minimum 3 patient . A two-parameter Bayesian logistic regression model employ escalation overdose control principle use escalation phase dose level selection determination MTD RD .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm diagnosis prostate cancer Histologically cytologically confirm locally advance metastatic breast cancer Patients untreated and/or symptomatic metastatic CNS disease Prior anaphylactic severe infusion reaction Treatment agent affect prolactin level Active autoimmune disease Other protcoldefined Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>castration-resistant prostate cancer , advance breast cancer</keyword>
</DOC>